Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02979730 · ClinicalTrials.gov registry record · NA

Impact of Rapid Flu Testing in BMC ED

A NA study, sponsored by Boston Medical Center.

Completed
Registry status
NA
Development phase
233
Enrollment target

NCT02979730 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 233 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02979730, a NA study, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
NA
Development phase
233 participants
Enrollment target

Study Summary

The purpose of the study is to compare Emergency Department patients who undergo influenza testing using an FDA-approved point-of-care device (Cobas Liat Influenza A/B assay) located in the ED, to patients whose samples are sent to the BMC central laboratory. Patients who agree to participate will have their samples randomly assigned to be tested on either at the core lab, or on the POC device. The current turnaround time for samples sent to the laboratory is approximately two hours; investigators expect that the point of care device can reduce this time. Investigators will determine if the time to disposition and the administration of antibiotics is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing

Interventions

  • OTHER Core Lab Test
  • OTHER ED Point of Care Test

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2017-02-07
Est. Completion 2017-12-01
Phase NA

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT02979730

The ClinicalTrials.gov registry entry for NCT02979730 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Core Lab Test is the first listed.

NCT02979730 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02979730 about?

NCT02979730 is a clinical study titled "Impact of Rapid Flu Testing in BMC ED". The purpose of the study is to compare Emergency Department patients who undergo influenza testing using an FDA-approved point-of-care device (Cobas Liat Influenza A/B assay) located in the ED, to patients whose samples are sent to the BMC central laboratory. Patients who agree to participate will h...

What is the current status of trial NCT02979730?

This trial is currently completed. It is a NA study. The enrollment target is 233 participants. The study started on 2017-02-07. Estimated completion is 2017-12-01.

What interventions are being tested in trial NCT02979730?

The interventions under investigation include: Core Lab Test (OTHER), ED Point of Care Test (OTHER).

Who is sponsoring clinical trial NCT02979730?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.